Senior Citizen's Guide digital books
Senior Citizen's Guide to Pittsburgh

AIO Clinical Trials

AIO is excited to announce a new clinical trial now open to patients with dry age-related macular degeneration.  AIO is the only practice in the area to participate.

The partners at AIO would like to introduce a new clinical research study that is now open to the public.  Age-related macular degeneration affects as many as 15 million Americans and millions more around the world. The disease attacks the macula of the eye, where our sharpest central vision occurs. Although it rarely results in complete blindness, it robs the individual of all but the outermost, peripheral vision, leaving only dim images or black holes at the center of vision.

There are several forms of macular degeneration, but the fastest growing form is age-related macular degeneration (AMD).  AMD is the number one cause of severe vision loss and legal blindness in adults over 60 in the U.S. As our population ages, and the "baby boomers" advance into their 60's and 70's, we will see a virtual epidemic of AMD. Perhaps 14%-24% of the U.S. population aged 65-74 years and 35% of people aged 75 years or more have the disease.

This clinical research will evaluate the safety and efficacy of the investigational drug manufactured by GlaxoSmithKline.  This investigational drug, all study examinations and tests will be at NO COST TO THE PATIENT.  The patient must be willing and able to make it to several visits as they will receive 18-monthly intravenous infusions.  AIO is the ONLY practice in Western Pennsylvania to be able to offer this study and are happy to evaluate ANY patient for participation in this clinical trial.

For more information on this clinical trial, please contact Lesley M. Holot at 412-653-3080 ext 1041.

Visit AIO Senior Citizen's Guide Profile

 

Home    Featured Programs    Choose Local Area     Request Information
A JR Media Publication • www.jrmediallc.comSite Index